Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)’s share price traded up 3.6% during mid-day trading on Monday . The stock traded as high as $76.33 and last traded at $75.42, with a volume of 487,148 shares traded. The stock had previously closed at $72.78.

Several equities analysts have issued reports on the company. Goldman Sachs Group Inc. reiterated a “neutral” rating and set a $65.00 target price (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 10th. Zacks Investment Research raised Alnylam Pharmaceuticals from a “sell” rating to a “buy” rating and set a $85.00 price target on the stock in a research note on Tuesday, August 9th. Cowen and Company reissued a “buy” rating and set a $150.00 price target on shares of Alnylam Pharmaceuticals in a research note on Sunday, August 7th. Needham & Company LLC reissued a “buy” rating and set a $152.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, August 5th. Finally, JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, August 5th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $113.62.

The firm’s market cap is $6.49 billion. The firm has a 50-day moving average price of $68.33 and a 200 day moving average price of $63.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter in the prior year, the business earned ($0.85) EPS. Alnylam Pharmaceuticals’s revenue was up .2% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals Inc. will post ($4.69) earnings per share for the current year.

In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the transaction, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

An institutional investor recently raised its position in Alnylam Pharmaceuticals stock. BlackRock Advisors LLC increased its position in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 8.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 179,529 shares of the biopharmaceutical company’s stock after buying an additional 13,612 shares during the period. BlackRock Advisors LLC owned 0.21% of Alnylam Pharmaceuticals worth $16,901,000 as of its most recent SEC filing.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.